Business Context and Reporting Period
Xencor, Inc. (XNCR) filed a Form 8-K on March 4, 2026, reporting the termination of a Material Definitive Agreement. The filing addresses the end of the Amended and Restated Collaboration and License Agreement with Genentech, Inc. and F. Hoffmann-La Roche Ltd.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on the contractual termination event.
Material Changes
- Agreement Termination: Genentech elected to terminate the collaboration agreement in its entirety for convenience.
- Effective Date: The termination is effective as of September 4, 2026.
- Product Impact: The agreement covered efbalropendekin alfa, an engineered cytokine-Fc fusion protein, which was the sole active collaboration product. Roche previously removed this asset from its development pipeline in January 2025.
- Development Status: Xencor ceased cost-sharing development activities in the first half of 2024, opting out of co-development. Genentech had assumed sole responsibility for clinical, regulatory, and commercial activities prior to this termination.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance or management commentary regarding future outlook. The primary risk disclosed is the loss of the collaboration with Genentech/Roche, which was anticipated following Roche's 2024 pipeline announcement. No unusual items or contingencies beyond the termination were detailed in this specific report.
Investor Verification Checklist
- Verify the financial impact of the termination on Xencor's future revenue streams and milestone payments.
- Confirm whether any termination fees or final payments are due from Genentech/Roche.
- Review the status of any intellectual property rights reversion upon the September 4, 2026 effective date.
- Assess the impact on Xencor's cash burn rate given the cessation of cost-sharing activities in 2024.